There’s no word yet on when Metagenomi will enter the clinic.
In its first quarterly update as a public company, the California biotech said Wednesday that its cash runway is set to take it into 2027 and bankroll two INDs along the way, but it was mum on when the first study could begin.
That didn’t surprise analysts since Metagenomi went public last month in one of the most high-profile preclinical IPOs in recent memory. The company is attempting to find new enzymes and create gene-editing tools.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.